Haleon plc ADR (HLN) is slightly overvalued and Teva- Pharmaceutical Industries Ltd (TEVA) is overvalued.
Both trade above our estimate of their intrinsic value. HLN is the closer of the two: -14%, against -92% for TEVA.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $8.10; the price of $9.25 is 14% above that value, and 76% of that value comes from beyond year five.
Leak Score 27/100 on 3 of 12 signals
Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $20.57; the price of $39.52 is 92% above that value, and 77% of that value comes from beyond year five.
Leak Score 0/100 on 3 of 12 signals
| Metric | HLN | TEVA |
|---|---|---|
| Verdict | Slightly overvalued | Overvalued |
| Price | $9.25 | $39.52 |
| Intrinsic value | $8.10 | $20.57 |
| Margin of safety | -14% | -92% |
| Leak Score | 27/100 (3/12) | 0/100 (3/12) |
| Market cap | $40.7B | $46.1B |
| Revenue growth, 5 years | 2.8% | 0.8% |
| Operating margin | 23.3% | 18.8% |
| Net margin | 14.6% | 4.1% |
| Return on equity | 10.0% | 9.7% |
| Debt to equity | 0.50 | 2.18 |
| P/E | 19.0x | 65.9x |
| Forward P/E | 15.0x | 12.9x |
| P/B | 1.9x | 5.9x |
| Dividend yield | 2.4% | — |